Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems

BACKGROUND: Immune checkpoint inhibitors-induced myocarditis presents unique clinical challenges. Here, we assessed post-marketing safety of cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), programmed cell death-1 (PD-1), and programmed death-ligand 1 (PD-L1) inhibitors by mining the real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Rulan, Wang, Quanziang, Meng, Deyu, Li, Kang, Zhang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791701/
https://www.ncbi.nlm.nih.gov/pubmed/33413213
http://dx.doi.org/10.1186/s12885-020-07741-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791701/
https://www.ncbi.nlm.nih.gov/pubmed/33413213
http://dx.doi.org/10.1186/s12885-020-07741-0

Ejemplares similares